Entering text into the input field will update the search result below

Qualigen partners Hande Sciences to support its application enabling studies for QN-302

Jul. 06, 2022 10:07 AM ETQualigen Therapeutics, Inc. (QLGN)By: Anuron Mitra, SA News Editor
  • Qualigen Therapeutics (NASDAQ:QLGN) on Wednesday said it would partner China-based Hande Sciences to scale-up manufacturing to support investigational new drug application enabling studies for its QN-302 inhibitor platform.
  • QLGN is developing QN-302 as a potential treatment for a type of pancreatic

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About QLGN

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Qualigen Therapeutics, Inc.
First Wave BioPharma, Inc.
Aridis Pharmaceuticals, Inc.
Ensysce Biosciences, Inc.
Cyclacel Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.